These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 18519237

  • 1. Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.
    Kowal K, Zukowski S, Moniuszko M, Bodzenta-Łukaszyk A.
    Folia Histochem Cytobiol; 2008; 46(2):193-8. PubMed ID: 18519237
    [Abstract] [Full Text] [Related]

  • 2. Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.
    Kowal K, Moniuszko M, Zukowski S, Bodzenta-Lukaszyk A.
    Folia Histochem Cytobiol; 2010 Dec; 48(4):518-23. PubMed ID: 21478092
    [Abstract] [Full Text] [Related]

  • 3. Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge.
    Kowal K, Bodzenta-Lukaszyk A, Pampuch A, Szmitkowski M, Donati MB, Iacoviello L.
    Int Arch Allergy Immunol; 2007 Dec; 144(3):240-6. PubMed ID: 17579282
    [Abstract] [Full Text] [Related]

  • 4. The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients.
    Pampuch A, Kowal K, Bodzenta-Lukaszyk A, Di Castelnuovo A, Chyczewski L, Donati MB, Iacoviello L.
    Allergy; 2006 Feb; 61(2):234-8. PubMed ID: 16409202
    [Abstract] [Full Text] [Related]

  • 5. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B.
    Oncol Rep; 2003 Feb; 10(3):635-9. PubMed ID: 12684636
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
    Qian J, Li B, Yin M, Shen P, Sun K.
    Zhonghua Er Ke Za Zhi; 2015 Jun 15; 53(6):453-8. PubMed ID: 26310557
    [Abstract] [Full Text] [Related]

  • 14. [Effects of acupoint-embedment of medicated-thread and acupoint-injection on expression of cortical urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in rats with cerebral ischemia-reperfusion injury].
    Kong LH, Ye YW, Zhou H, Zhou HJ, Du YJ, Cui CX.
    Zhen Ci Yan Jiu; 2010 Dec 15; 35(6):409-14. PubMed ID: 21375013
    [Abstract] [Full Text] [Related]

  • 15. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 15; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR, Wang Q, Shi SS, Lu MH, Guo WD.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb 15; 12(2):82-4. PubMed ID: 14980106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.